Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends

JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends

JMP Securities’ Michael G. King, Jr. believes there is limited near-term upside for Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), given the prescription trends and the ongoing scrutiny of Iclusig's pricing.

King downgraded the rating on the company from Market Outperform to Market Perform.

The analyst believes that Iclusig metrics would most be in line with the estimates and “key catalysts from the brigatinib ESMO data and Japanese approval of Iclusig are in the rear-view mirror; value-driving catalysts are also limited, in our view, with only FDA approval of brigatinib remaining in 2016.”

Political Scrutiny

King also believes the recent scrutiny of Ariad’s pricing policies by members of the U.S. Senate and House of Representatives could have a “two-fold” effect of capping the premium multiple that the market was willing to assign to Iclusig revenues, while leading to the risk of adverse publicity for the company or a potential modification of Iclusig’s pricing.

“In our opinion, either outcome does not bode favorably for share performance near term; hence, we believe shares are fairly valued at current levels,” the analyst stated.

King pointed out that given the potential for continued political scrutiny, any additional increase in pricing to a “higher equilibrium” would be “a risky strategy at best.”

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for ARIA

Jan 2017DowngradesBuyHold
Jan 2017UpgradesUnderweightEqual-Weight
Jan 2017DowngradesBuyHold

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: JMP Securities Jr. Michael G. KingAnalyst Color Downgrades Analyst Ratings Best of Benzinga


Related Articles (ARIA)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Benzinga's Top Initiations

The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind